Total Payments
$399,183
2024 Payments
$6,078
Companies
24
Transactions
415
Medicare Patients
896
Medicare Billing
$115,773
Payment Breakdown by Category
Consulting$267,966 (67.1%)
Other$57,683 (14.5%)
Research$29,988 (7.5%)
Travel$23,350 (5.8%)
Food & Beverage$15,662 (3.9%)
Education$4,535 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $267,966 | 73 | 67.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $41,937 | 13 | 10.5% |
| Unspecified | $29,988 | 32 | 7.5% |
| Travel and Lodging | $23,350 | 93 | 5.8% |
| Food and Beverage | $15,662 | 189 | 3.9% |
| Honoraria | $12,581 | 3 | 3.2% |
| Education | $4,535 | 11 | 1.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,165 | 1 | 0.8% |
Payments by Type
General
$369,195
383 transactions
Research
$29,988
32 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EMD Serono, Inc. | $82,077 | 89 | $0 (2024) |
| Genentech USA, Inc. | $55,500 | 56 | $0 (2024) |
| Genentech, Inc. | $53,940 | 47 | $0 (2024) |
| Merck KGaA | $42,850 | 4 | $0 (2021) |
| GENZYME CORPORATION | $29,454 | 35 | $0 (2024) |
| Biogen, Inc. | $27,220 | 55 | $0 (2023) |
| F. Hoffmann-La Roche AG | $23,385 | 29 | $0 (2024) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $19,897 | 16 | $0 (2022) |
| Celgene Corporation | $15,601 | 26 | $0 (2023) |
| Bayer HealthCare Pharmaceuticals Inc. | $14,782 | 16 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,078 | 17 | F. Hoffmann-La Roche AG ($3,608) |
| 2023 | $29,384 | 28 | Biogen, Inc. ($5,486) |
| 2022 | $38,358 | 45 | Genentech USA, Inc. ($11,720) |
| 2021 | $55,227 | 30 | EMD Serono, Inc. ($13,537) |
| 2020 | $44,224 | 38 | Merck KGaA ($14,190) |
| 2019 | $97,611 | 95 | Genentech, Inc. ($20,045) |
| 2018 | $55,125 | 80 | EMD Serono, Inc. ($18,237) |
| 2017 | $73,175 | 82 | EMD Serono, Inc. ($24,487) |
All Payment Transactions
415 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $143.96 | General |
| 12/06/2024 | Genentech, Inc. | Ocrevus (Biological) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $1,055.80 | Research |
| Study: Two-Year Analysis of Efficacy and Safety Data From Black and Hispanic People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial • Category: Immunology | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $555.53 | Research |
| Study: Two-Year Analysis of Efficacy and Safety Data From Black and Hispanic People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial • Category: Immunology | ||||||
| 09/18/2024 | Genentech USA, Inc. | Ocrevus (Biological), Ocrevus Zunovo | Food and Beverage | In-kind items and services | $95.67 | General |
| Category: Immunology | ||||||
| 09/18/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $53.17 | General |
| 07/31/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $114.01 | General |
| 07/22/2024 | Genentech, Inc. | Ocrevus (Biological) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Immunology | ||||||
| 07/15/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $144.54 | General |
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $911.14 | Research |
| Study: One-Year Analysis of Efficacy and Safety Data From Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial • Category: Immunology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $707.93 | Research |
| Study: One-Year Analysis of Ocrelizumab Treatment in Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis From the CHIMES Trial • Category: Immunology | ||||||
| 06/20/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $71.63 | General |
| Category: Rare Disease | ||||||
| 05/30/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $93.55 | General |
| 03/31/2024 | F. Hoffmann-La Roche AG | Ocrevus (Biological) | — | In-kind items and services | $378.00 | Research |
| Study: One-Year Analysis of Efficacy and Safety Data From Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial • Category: Immunology | ||||||
| 03/21/2024 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $130.87 | General |
| Category: Neuroscience | ||||||
| 03/14/2024 | EMD Serono, Inc. | Mavenclad (Drug) | Food and Beverage | Cash or cash equivalent | $117.74 | General |
| Category: Neurology | ||||||
| 02/23/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $4.03 | General |
| 12/21/2023 | Genentech, Inc. | Ocrevus (Biological) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: Immunology | ||||||
| 12/14/2023 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $134.11 | General |
| 11/17/2023 | Mylan Specialty L.P. | — | Travel and Lodging | Cash or cash equivalent | $80.47 | General |
| 11/13/2023 | Mylan Specialty L.P. | — | Consulting Fee | Cash or cash equivalent | $5,196.75 | General |
| 11/02/2023 | Genentech USA, Inc. | Ocrevus (Biological) | Consulting Fee | Cash or cash equivalent | $4,830.00 | General |
| Category: Immunology | ||||||
| 11/02/2023 | Genentech USA, Inc. | Ocrevus (Biological) | Travel and Lodging | Cash or cash equivalent | $11.04 | General |
| Category: Immunology | ||||||
| 10/11/2023 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $77.95 | General |
| 10/10/2023 | Genentech USA, Inc. | Ocrevus (Biological) | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $7,275 | 1 |
| AN OPEN-LABEL, MULTICENTER STUDY TO ASSESS DISEASE ACTIVITY AND BIOMARKERS OF NEURONAL DAMAGE IN MINORITY PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS RECEIVING TREATMENT WITH OCRELIZUMAB | F. Hoffmann-La Roche AG | $5,334 | 7 |
| AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS | F. Hoffmann-La Roche AG | $4,078 | 6 |
| Publication support research related | Novartis Pharma AG | $3,505 | 1 |
| Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab | F. Hoffmann-La Roche AG | $2,199 | 2 |
| Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) | Biogen, Inc. | $1,808 | 7 |
| Two-Year Analysis of Efficacy and Safety Data From Black and Hispanic People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial | F. Hoffmann-La Roche AG | $1,611 | 2 |
| DEMOGRAPHICS AND BASELINE DISEASE CHARACTERISTICS OF BLACK AND HISPANIC PATIENTS WITH MULTIPLE SCLEROSIS ENROLLED IN THE CHIMES TRIAL | F. Hoffmann-La Roche AG | $1,381 | 2 |
| One-Year Analysis of Efficacy and Safety Data From Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis Receiving Ocrelizumab Treatment in the CHIMES Trial | F. Hoffmann-La Roche AG | $1,289 | 2 |
| Demographics and Baseline Disease Characteristics of Black and Hispanic Patients With Multiple Sclerosis in the Open-Label, Single-Arm, Multicenter, Phase IV CHIMES Trial | F. Hoffmann-La Roche AG | $799.08 | 1 |
| One-Year Analysis of Ocrelizumab Treatment in Black/African American and Hispanic/Latino People With Relapsing Multiple Sclerosis From the CHIMES Trial | F. Hoffmann-La Roche AG | $707.93 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 211 | 283 | $137,165 | $27,227 |
| 2022 | 6 | 242 | 359 | $150,724 | $32,274 |
| 2021 | 5 | 205 | 264 | $132,183 | $29,258 |
| 2020 | 6 | 238 | 307 | $138,976 | $27,015 |
Total Patients
896
Total Services
1,213
Medicare Billing
$115,773
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 63 | 83 | $46,937 | $9,285 | 19.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 83 | 96 | $33,982 | $6,838 | 20.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 23 | 46 | $18,944 | $4,681 | 24.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 31 | 31 | $29,648 | $4,596 | 15.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 27 | $7,654 | $1,827 | 23.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 64 | 89 | $47,709 | $10,402 | 21.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 97 | 117 | $39,834 | $8,768 | 22.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 25 | 60 | $24,088 | $5,104 | 21.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 23 | 59 | $16,240 | $3,622 | 22.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 21 | 21 | $19,240 | $3,579 | 18.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 12 | 13 | $3,613 | $799.27 | 22.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 80 | 115 | $60,373 | $13,818 | 22.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 65 | 71 | $23,524 | $5,366 | 22.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 24 | 24 | $21,624 | $4,145 | 19.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 19 | 37 | $14,053 | $3,292 | 23.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 17 | 17 | $12,609 | $2,636 | 20.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 103 | 131 | $66,658 | $11,320 | 17.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 30 | 30 | $25,900 | $5,317 | 20.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 21 | 49 | $18,241 | $4,432 | 24.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 39 | 40 | $11,760 | $2,529 | 21.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 31 | 33 | $10,313 | $1,918 | 18.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 14 | 24 | $6,104 | $1,498 | 24.5% |
About Dr. Anthony Reder, MD
Dr. Anthony Reder, MD is a Neurology healthcare provider based in Burr Ridge, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/16/2007. The National Provider Identifier (NPI) number assigned to this provider is 1467503441.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Reder, MD has received a total of $399,183 in payments from pharmaceutical and medical device companies, with $6,078 received in 2024. These payments were reported across 415 transactions from 24 companies. The most common payment nature is "Consulting Fee" ($267,966).
As a Medicare-enrolled provider, Reder has provided services to 896 Medicare beneficiaries, totaling 1,213 services with total Medicare billing of $115,773. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Burr Ridge, IL
- Active Since 01/16/2007
- Last Updated 07/08/2007
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1467503441
Products in Payments
- OCREVUS (Biological) $108,876
- Mavenclad (Biological) $30,152
- Ocrevus (Biological) $20,200
- Betaseron (Drug) $14,782
- NO PRODUCT DISCUSSED (Drug) $13,637
- Rebif (Biological) $12,627
- Mavenclad (Drug) $11,710
- AUBAGIO (Drug) $8,405
- TYSABRI (Biological) $8,291
- TECFIDERA (Drug) $8,194
- GILENYA (Drug) $7,485
- ARZERRA (Drug) $7,275
- Glatiramer Acetate (Drug) $6,567
- PLEGRIDY (Biological) $5,363
- UPLIZNA (Drug) $3,799
- FTY720D_GILENYA_NEUROSCIENCE (Drug) $3,505
- ZEPOSIA (Drug) $3,036
- Ponvory (Drug) $3,000
- Ozanimod (Drug) $2,337
- ZINBRYTA (Biological) $2,285
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Burr Ridge
Amara Mian, Do, DO
Neurology — Payments: $4,204
Neurology $4,204
Martin Nicholas, Md, MD
Neurology — Payments: $117.25
Neurology $117.25
Ewa Chelmicka Schorr, Md, MD
Neurology — Payments: $1.17
Neurology $1.17
John Ebersole, Md, MD
Neurology
Neurology
Richard Kraig, Md, Phd, MD, PHD
Neurology
Neurology
Avertano Noronha, Md, MD
Neurology
Neurology